A股異動丨上海凱寶(300039.SZ)大漲逾7% 擬投資2400萬元就YKRH00020霧化吸入溶液項目合作開發
格隆匯8月16日丨上海凱寶(300039.SZ)大漲逾7%,報5.45元,高見5.62元創歷史新高,總市值57億元。上海凱寶公吿,公司與北京盈科瑞創新藥物研究有限公司就YKRH00020霧化吸入溶液項目合作開發簽訂合同,公司以2400萬元受讓YKRH00020霧化吸入溶液臨牀前研究成果、臨牀試驗許可及研究資料、有關國內專利及其技術80%的產權,受讓完成後,雙方共同推動上述項目的開發。合同涉及的項目是主要用於兒童和老年患者給藥的呼吸疾病類霧化吸入製劑項目。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.